EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: A case report and review of the literature

被引：7

作者：

Sperandio, Rubens Copia ^{[1
]}

Teixeira Tostes, Francinne Luiza ^{[1
]}

Campregher, Paulo Vidal ^{[1
]}

Paes, Vitor Ribeiro ^{[1
]}

Moura, Fernando ^{[1
]}

Schvartsman, Gustavo ^{[1
]}

机构：

[1] Hosp Israelita Albert Einstein, Ctr Oncol & Hematol Einstein Familia Dayan Daycov, Sao Paulo, Brazil

来源：

LUNG CANCER | 2022年 / 166卷

关键词：

Non-small cell lung cancer; Molecular targeted therapy; Gene fusions; Molecular testing; KIF5B-EGFR FUSION; EGFR; VARIANT;

D O I：

10.1016/j.lungcan.2022.02.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Comprehensive next-generation sequencing panels are leading to detection of rare gene fusion events. EFGRRAD51 fusion is a rare oncogenic finding and clinical data for management of this condition is scarce. We report a widely metastatic non-small cell lung cancer in a never-smoker young male patient with sustained near complete systemic and intracranial response to osimertinib, a third-generation EGFR tyrosine-kinase inhibitor (TKI). We also review the available data of other TKIs in this scenario and underscore the role of comprehensive molecular testing for NSCLC.

引用

页码：94 / 97

页数：4

共 50 条

[1] Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report
Lai, Sunny Y.
Richardson, Noah H.
Tran, Mya
Hanna, Nasser H.
Shields, Misty D.
[J]. JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
[2] EGFR-RAD51 fusion variant in lung adenocarcinoma and response to erlotinib: A case report
Zhu, You-cai
Wang, Wen-xian
Xu, Chun-wei
Song, Zheng-bo
Du, Kai-qi
Chen, Gang
Lv, Tang-feng
Song, Yong
[J]. LUNG CANCER, 2018, 115 : 131 - 134
[3] EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report
Wang, W.
Xu, C.
Zhuang, W.
Song, Z.
Huang, Y.
Chen, Y.
Chen, G.
Fang, M.
Lv, T.
Song, Y.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S906 - S906
[4] Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an EGFR-RAD51 Fusion
Guan, Yan
Song, Zhanshuai
Li, Yan
Guog, Honglin
Shi, Junping
Zhang, Xuemei
Yao, Ming
[J]. ONCOLOGIST, 2019, 24 (08): : 1027 - 1030
[5] Primary Resistance to EGFR-TKIs in Lung Adenocarcinoma harboring EGFR-RAD51 Fusion: A Brief Report
Wang, H.
Peng, K.
Li, A.
Wang, Z.
Xie, Z.
Chen, H.
Wu, Y.
Yang, J.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S624 - S624
[6] EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature
Di Federico, Alessandro
Filetti, Marco
Palladini, Arianna
Giusti, Raffaele
Piras, Marta
De Giglio, Andrea
Ardizzoni, Andrea
Gelsomino, Francesco
[J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (03) : 497 - 503
[7] EGFR kinase domain duplication in lung adenocarcinoma with systemic and intracranial response to a double-dose of furmonertinib: a case report and literature review
Lin, Hong
Yang, Zhengyuan
Li, Zhifeng
Chen, Junwei
Wang, Hongbiao
Lin, Yingcheng
[J]. FRONTIERS IN ONCOLOGY, 2024, 14
[8] NCOA-RET fusion as a secondary resistance mechanism to osimertinib in complex EGFR-mutated lung adenocarcinoma: Case report and review of literature
Romagnolo, Alberto P.
Hino, Christopher
Mirshahidi, Saied
Chase, Kristina
Mirshahidi, Hamid
[J]. CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2023, 10
[9] Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report
Zhong, Rui
Li, Hui
Liu, Yanling
Zhang, Shuang
Liu, Jingjing
Huang, Zhicheng
Cheng, Ying
[J]. THORACIC CANCER, 2020, 11 (02) : 456 - 460
[10] Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature
Thumallapally, Nishitha
Yu, Hana
Farhan, Mohammad
Ibrahim, Uroosa
Odiami, Maricel
[J]. JOURNAL OF PHARMACY PRACTICE, 2018, 31 (02) : 244 - 248

← 1 2 3 4 5 →